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Abstract
Background: This planning study compares different radiotherapy techniques for patients with pituitary adenoma,
including flatness filter free mode (FFF), concerning plan quality and secondary malignancies for potentially young
patients. The flatness filter has been described as main source of photon scatter.
Material and methods: Eleven patients with pituitary adenoma were included. An Elekta Synergy™ linac was used
in the treatment planning system Oncentra® and for the measurements. 3D plans, IMRT, and VMAT plans and non-
coplanar varieties were considered. The plan quality was evaluated regarding homogeneity, conformity, delivery
time and dose to the organs at risk. The secondary malignancy risk was calculated from dose volume data and
from measured dose to the periphery using different models for carcinoma and sarcoma risk.
Results: The homogeneity and conformity were nearly unchanged with and without flattening filter, neither was
the delivery time found substantively different. VMAT plans were more homogenous, conformal and faster in delivery
than IMRT plans. The secondary cancer risk was reduced with FFF both in the treated region and in the periphery. VMAT
plans resulted in a higher secondary brain cancer risk than IMRT plans, but the risk for secondary peripheral cancer was
reduced. Secondary sarcoma risk plays a minor role. No advantage was found for non-coplanar techniques. The FFF
delivery times were not shortened due to additional monitor units needed and technical limitations. The risk for
secondary brain cancer seems to depend on the irradiated volume. Secondary sarcoma risk is much smaller than
carcinoma risk in accordance to the results of the atomic bomb survivors. The reduction of the peripheral dose and
resulting secondary malignancy risk for FFF is statistically significant. However, it is negligible in comparison to the risk in
the treated region.
Conclusion: Treatments with FFF can reduce secondary malignancy risk while retaining similar quality as with flattening
filter and should be preferred. VMAT plans show the best plan quality combined with lowest peripheral secondary
malignancy risk, but highest level of second brain cancer risk. Taking this into account VMAT FFF seems the most
advantageous technique for the treatment of pituitary adenomas with the given equipment.
Keywords: Pituitary adenoma, Treatment planning, Secondary malignoma risk, Flattening filter free
© The Author(s). 2020 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
* Correspondence: marius.treutwein@ukr.de
1Department for radiotherapy, Regensburg University Medical Center,
Regensburg, Germany
Full list of author information is available at the end of the article
Treutwein et al. BMC Cancer           (2020) 20:88 
https://doi.org/10.1186/s12885-020-6535-y
Background
Radiotherapy of pituitary adenomas is often applied as
postoperative therapy of tumors that cannot be removed
completely. For over one decade patients with pituitary
adenoma have been treated primarily with two parallel op-
posed fields or a three field technique [1–7]. Only a few
recent publications describe the application of intensity
modulated radiotherapy (IMRT) or volumetric modulated
arc (VMAT) technique in this region [8–10], none of
them mentioning the flatness filter free (FFF) mode. FFF is
applicable in combination with fluence modulating tech-
niques like IMRT or VMAT. In this mode a considerably
higher dose rate is achieved by omitting the flatness filter.
This planning study compares different plans for patients
with pituitary adenoma. The plans were optimized using
both modes: flattened beam (FB) and FFF. The flatness fil-
ter has been described as the main source of photon scat-
ter in the treatment head [11]. Additional peripheral dose
resulting from this contribution has been confirmed in
some publications referring to other entities [12–18] and
increases the risk for secondary malignancies. Pituitary ad-
enomas represent about 10% of all intracranial tumors
[19]. The incidence increases over the years, starting at
about an age of 10 years and has a possible decline in high
age [20]. Therefore, the risk for secondary malignancies
should be considered. The aim of this study is to evaluate
statistically significant differences for FB and FFF plans re-
garding the plan quality and the risk for secondary malig-
nancies in the treated region and the periphery. Plans with
two and three fixed beams were taken as reference.
Material and methods
Patients
Data sets of 11 patients (five female, six male) with pituit-
ary adenoma were used for this retrospective planning
study. All patients have got a cranial X-ray CT scan in su-
pine positioning with the head in neutral position. The
head was immobilized using thermoplastic mask systems.
The CT scans were fused with the pretherapeutic cranial
MRI (contrast enhanced T1-weighted sequence). GTV,
CTV and PTV as well as organs at risk were delineated
using the treatment planning system (TPS) Oncentra® Ex-
ternal Beam v4.5 (Nucletron®, an Elekta company) on all
axial slices. The GTV included the macroscopic (residual)
tumor volume. The CTV was based on GTV extended for
the resection cavity in postoperative cases. The PTV was
defined by CTV plus an isotropic margin of 3–5mm, de-
pending on setup error and reproducibility of positioning.
Linear accelerator
We used a linear accelerator (linac) of type Elekta Syn-
ergy™ with Agility™ head (Elekta AB, Stockholm, Sweden)
operated by the desktop software Integrity 3.1 and record
and verify system Mosaiq 2.50. The head is equipped with
80 interdigitating leaf pairs, projecting a leaf width of
5 mm to the isocenter. For all plans 6 MV photons
were used. The beam quality of both modes FB and
FFF has been shown to be equivalent for this machine
type [21, 22]. The linac offers a maximum dose rate
of 550 MU per minute in FB mode and 1700 MU per
minute in FFF.
Treatment planning
The planning was performed with TPS Oncentra® Exter-
nal Beam using the collapsed cone algorithm. A grid size
of 2 mm has been chosen. Variable gantry speed with a
set maximum value of 6.0 degree per second is sup-
ported by the software. The variable dose rate was set to
a minimum value of 20 MU per minute. A dynamic and
static minimum leaf gap of 1.0 cm had to be observed.
The optimizer module in Oncentra® used the step-and-
shoot algorithm for IMRT optimizations [23]. This mod-
ule has been developed by RaySearch Laboratories
(Stockholm, Sweden) and therefore has the same roots
as the SmartArc module in Pinnacle3 TPS (Philips,
Amsterdam, Netherlands) and the proprietary develop-
ment RayArc module in RayStation TPS.
The objectives for the PTV were set to a minimum dose
of 49.4 Gy and a maximum dose of 51.4 Gy in 28 fractions,
aiming for a fraction dose of 1.8 Gy. A uniform dose object-
ive to 50.4 Gy was added to improve the homogeneity. Fur-
ther objectives were set for the following organs at risk
(OAR) (Table 1) according to [24–26]: brain, brainstem,
chiasm, both lenses, bulbs, lacrimal glands, and parotids.
Additionally, the surrounding dose fall-off objective has
been applied to shape the dose gradient from the PTV into
the normal tissue [27]. It supports an improvement of the
conformity. The same set of dose volume objectives has
been used for all plans to get comparable results [12, 18,
28, 29]. The aim of this set was to keep the risk for the
OARs on an acceptable level, but to leave freedom for the
optimizer to achieve good conformity and homogeneity.
In both modes (FB and FFF) IMRT plans with nine
equispaced coplanar fields were generated; in a second
variant a tenth non-coplanar field was added. Similarly
two different VMAT plans were optimized: one single
arc rotation (182°-178°), and the second with an added
half rotation in the sagittal patient plane (0°-180°).
The average dose to the PTV was set to 100% after
the optimization process. An average dose value in a
range of 50.4 Gy ± 0.8 Gy - which represents an inter-
val of about 1.5% around the target value – was ac-
cepted in the sense of a dose prescription according
to ICRU 83 [30]. No rescaling has been performed as
this would have affected the dose to the normal tissue
and organs at risk which are also part of the
optimization process [31].
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Plan evaluation
The following parameters were evaluated: the average
dose to the PTV Dav
PTV, homogeneity index HI, and the
conformity index CI. For HI the definition of ICRU re-
port 83 [30] was used: HI = (D2%
PTV – D98%
PTV)/Dav
PTV
with D2%
PTV and D98%
PTV as dose to 2 and 98% of the
PTV. CI was defined according to Paddick [32]: CI =
TV49.4 Gy
2/(V49.4 Gy x V
PTV). TV49.4 Gy is the volume
within the PTV which receives at least 49.4 Gy, V49.4 Gy
is the volume enclosed by the corresponding isodose
within the complete patient contour, and VPTV is the
volume of the PTV. For all plans the observance of the
objectives for the OAR was investigated and regarded as
criterion of acceptability.
Measurements
The evaluation of the peripheral dose (PD) was performed
using the upper part of a male Alderson phantom (RSD
Inc., Long Beach, CA, USA) (Fig. 1). Two slabs of the
phantom were replaced by copies of PA material with
bores for ionization chambers. The first chamber in a
distance of 16.3 cm from isocenter corresponded to the
position of the thyroid gland, the second in a distance of
30.3 cm in the upper thoracic region corresponded to an
esophageal position. The dose to these points, PDthyr and
PDesoph has been measured with chambers type M30016
(0.3 cm3) and M23331 (1.0 cm3), respectively, both con-
nected to Unidos dosimeters (PTW, Freiburg, Germany).
It is reasonable to assume an uncertainty of 5% for these
Table 1 Treatment planning objectives
Regions of interest Dose level in Gy Volume in % Dose volume objective type Weight
Brain 20 20 Maximum dose volume 300
30 10 Maximum dose volume 300
40 5 Maximum dose volume 300
Brainstem 51.4 0 Maximum dose 500
Chiasm 50 0 Maximum dose 300
Lens 15 0 Maximum dose 30
Bulb 35 50 Maximum dose volume 100
Lacrimal gland 20 50 Maximum dose volume 30
Parotid 30 50 Maximum dose volume 100
Outline 51.4 0 Maximum dose 5000
49.4–25.0 Surrounding dose falloff, distance 1 cm 3000
PTV 49.9 100 Minimum dose 3000
51.4 0 Maximum dose 3000
50.4 Uniform dose 1000
Fig. 1 Setup of the Alderson phantom for the peripheral dose measurements. The ionization chambers are inserted in the white slabs. The arrow
indicates the isocenter plane
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measurements considering the statistical uncertainty, the
positioning inaccuracy and the calibration of the detector
for megavoltage beam quality [33].
The plan verifications were accomplished with the SRS
MapCHECK™ array and StereoPHAN™ phantom equip-
ment (Fig. 2) in combination with the SNS Patient™ soft-
ware version 8.1 (Sun Nuclear Corporation, Melbourne,
FL, USA). The array is a rather new developed device. Its
size is 77 × 77mm2, the diodes have a spacing of 2.47mm.
The active detector area is 0.48 × 0.48mm2. The signals
are sampled with a frequency of 20Hz. Gantry angles are
analyzed by the angular dependency of two opposing de-
tector planes. Therefore, no gantry angle sensor is neces-
sary. The phantom has already been used with other
modular inserts for films [34] and ionization chambers.
The system is especially designed for small volumes.
We applied a hybrid plan verification as described for
other systems [35–37] transferring the patient plan un-
changed to the phantom and performing a dose calcula-
tion on the phantom with a dose grid of 1mm. A CT scan
of the phantom has been offered by the manufacturer,
slices in 1mm distance; a uniform relative mass density of
1.2 has been assigned to the external structure as recom-
mended. The array was positioned horizontally in the
isocenter plane.
The software assists a cross-calibration procedure.
Offered shifts of the measured profiles relative to the
calculated ones for best coincidence were accepted,
but were clearly smaller than 1.0 mm. The measured
and calculated dose distributions were evaluated by
the gamma index [38] with a dose tolerance of 3%
referring to the maximum dose and a distance to
agreement of 3 mm. The area of the evaluation was
confined to dose values above 10% of the dose max-
imum [39].
As an additional plan quality parameter the delivery
time (DT) was recorded from pressing the beam on but-
ton until the last beam off.
Secondary malignancy risk
The calculations for the risk of secondary malignancies
use the models presented by Schneider et al. [40]. Their
work combines the data of the Japanese A-bomb survi-
vors [41] and secondary cancer data of Hodgkin’s pa-
tients from a Western population [42]. The excess
absolute risk (EAR) describes the risk of malignancy in-
cidence after irradiation. It is expressed as absolute dif-
ference of the number of malignancies in comparison to
an untreated control group. Commonly it is given per
10.000 persons per year. It is a function of the dose d,
the sex s, the age at exposure e and the attained age a.
EAR ðd; s; e; aÞ ¼ μ ðs; e; aÞ  f ðdÞ
In the present work gender averaged values are used.
Therefore, the parameter s can be neglected. Using the tables
given in [40], the EAR can be calculated from the dose vol-
ume data from the TPS for different organs of volume VT:
EARorg ¼ 1
VT
X
i
V ðDiÞ  βEAR  REDðDiÞ
 μ ðe; aÞ
The summation is performed over all voxels of the organ
with dose entry Di. μ can be used to calculate the risk
for different ages (e: age at exposition, a: attained age):
μ e; að Þ ¼ exp γe e−30ð Þ þ γa ln
a
70
  
The parameters γe and γa were derived by Preston et al.
[41]. For our calculations we have chosen e = 35 years,
Fig. 2 Setup for the plan verification with SRS MapCHECK™ array inserted in the StereoPHAN™ phantom
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which is close to the mean age given by Yamanaka et al.
[43] (37 years) and corresponds to the mean age minus
one standard deviation by Jiang et al. [44]. The attained
age was set to a = 70 years.
βEAR is the initial slope, the risk equivalent dose RED
the dose dependent part, for which Schneider et al.
present different models for carcinoma induction:
 The mechanistic model which considers cell killing
and fractionation effects
 The bell-shaped dose response model which neglects
any repopulation or repair effect
 The plateau model with full repopulation or repair
The mechanistic model is given by the form
RED Dð Þ ¼ e
−α0D
α0R
1−2Rþ R2eα0D− 1−Rð Þ2eα0R1−RD
 
assuming a fractionated treatment schedule of single
fractions with dose d up to a total dose D. α’ has been
derived from the linear quadratic model, assuming α/
β = 3 Gy for all tissues.
α0 ¼ αþ βd
R is the repopulation and repair parameter and equals 0
for no and 1 for full repair or repopulation. The bell-
shaped model is got in the limit of R to 0:
RED Dð Þ ¼ D e−α0D
In the limit of R to 1 the plateau model is described:
RED Dð Þ ¼ 1−e−α0D
 
=α0
The authors emphasize that there is only little know-
ledge yet about the dose-response relationships in the
investigated dose range [40]. The data could not be fit-
ted by all models for all organs, not even the most com-
plex mechanistic model. Therefore, we performed our
calculations for all three models.
At last we also applied the model for sarcoma induc-
tion of bone and soft tissue. The formula is quite similar
to the mechanistic model for carcinoma induction with
one additional term:
RED Dð Þ ¼ e
−α0D
α0R
1−2Rþ R2eα0D− 1−Rð Þ2eα0R1−RD−α0RD
 
We confined our calculations to an intermediate re-
population and repair effect with R = 0.5. βEAR, γe, and γa
are given in Table 2 for the investigated organs.
The two peripheral dose points were situated in the
low dose region. It has been shown by Preston et al. [41]
that for these points up to a total dose of 2 Gy the sim-
ple linear model is applicable.
EARorg ¼ βEAR  D μ ðe; aÞ
The factors βEAR for the selected OAR were taken
from this publication and applied according [40]. They
are given per 10.000 persons per year and Gy as 1.2 for
the thyroid gland and 0.58 for the esophagus. For the
esophagus no age dependency has been found. The age
correction factor μ(e,a) for secondary cancer risk in the
thyroid gland was calculated with γe and γa from Table
2. For this calculation the measured point dose has been
taken representative for the whole organ.
Statistics
An a priori power analysis has been performed to deter-
mine the sample size using the software G*Power ver-
sion 3.1.9.2 [45, 46]. We set α = 0.05, power (1-β) = 0.8,
and the effect size to 1.0. The Wilcoxon signed-rank test
for paired samples was chosen as statistical test, as it
does not require a normal distribution of the variables.
Taking various parent distributions into account (nor-
mal, Laplace, logistic) the maximum sample size of N =
11 for a normal distribution was selected.
IBM® SPSS® Statistics v23 (IBM Corporation, Armonk,
NY, USA) was applied to perform the Wilcoxon test
with a significance level of 0.05. The Bonferroni-Holm
method was used to control the maximum experiment-
wise error rate for multiple testing [47]. Five variables
were considered in this process: HI, CI, DT, the sum of
all calculated EAR from the dose volume histograms
EARsum
plan, and the sum of the EAR calculated from the
PD measurements EARsum
PD. Differences in the applica-
tion of VMAT and IMRT were investigated secondary
with a significance level of 0.05 without corrections for
multiple testing.
Results
Plan quality
Nearly all plans ended the optimization process with an
average dose in the PTV in the required interval as de-
scribed in the section “treatment planning” in material
and methods. Only one plan (VMAT FB) failed 0.2 Gy
below the required minimum value. All other treatment
plan objectives have been met in all plans except of the
chiasm. This objective has slightly been violated by
nearly all plans as the chiasm has been part of the PTV.
Table 2 Initial slope and age modifying parameters for EAR
calculation [40]
Organ at risk βEAR γe γa
Brain 0.51 −0.024 2.38
Soft Tissue 0.60 −0.013 −0.56
Bone 0.20 −0.013 −0.56
Thyroid – −0.046 0.6
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The maximum value of D2%
Chiasm was 1.7% above the
limit in Table 1. Fig. 3 demonstrates the dose distribu-
tion of all calculated plans in the isocenter plane for one
representative patient.
Fig. 4 shows the indexes HI and CI. No statistically
significant difference has been found for FB and FFF. HI
is equivalent for the classical 2Fd and 3Fd techniques
and all IMRT plans, but significantly improved for all
VMAT plans. CI is lowest for 2Fd plans, shows all IMRT
variants on one level and all VMAT variants again im-
proved on a significantly higher level.
In Fig. 5 the delivery time DT is presented for the co-
planar plans. For IMRT the difference of FB and FFF is
not significant, for VMAT the FFF mode needs statisti-
cally significant more time. However, the difference is
small (7 s). VMAT takes about the same time as two op-
posing fields (2Fd) and is faster than 3Fd and takes less
than half the time of IMRT. The non-coplanar plans
have not been evaluated in detail. Sample measurements
have shown that for our local conditions nearly 2 mins
additional time are required to enter the treatment room
and arrange gantry and table position.
Secondary malignancy risk
Fig. 6 illustrates the EAR for secondary brain cancer de-
pending on the technique and mode for the mechanistic
model. The other two models are not shown in the fig-
ure to gain more clarity. For fluence modulating tech-
niques the values for the bell-shaped model were about
10% higher, for the plateau model about 8% higher than
for the mechanistic model. For the 2Fd and the 3Fd
technique the differences between the models were up
to 19%, but again the bell-shaped model above the plat-
eau model. The reduction of EAR by application of FFF
instead of FB is statistically significant. Although the dif-
ference between both groups is very small, the signifi-
cance of the statistics can be explained by the pairing of
the samples in the Wilcoxon test: for all 11 pairings, the
value for FFF was lower than for FB. The lowest risk is
achieved by the simplest technique (2Fd). The differ-
ences between the three models are small. The non-
coplanar techniques IMRT10 and VMAT2 create a
higher risk than the coplanar techniques.
Fig. 7 a and b show the EAR for secondary sarcoma.
The risk is one magnitude smaller than for secondary
cancer. It is very similar for all techniques. There is
nearly no difference between FB and FFF.
The EAR for secondary cancer in the periphery (thy-
roid and esophagus) has been derived directly from the
PD measurements. In both organs we took the point
dose as representative for the whole organ for our calcu-
lations as a simple approach. Sample measurements for
the non-coplanar techniques resulted in much higher
doses with factors from 6 to over 100 and were aborted.
Fig. 3 Isodose distributions in the isocenter plane for one
representative patient. The first row shows the classical 2 and 3 field
techniques, below in the left column plans with FB mode, in the
right column the FFF plans. From 2nd row to bottom: coplanar
IMRT, non-coplanar IMRT, coplanar VMAT, non-coplanar VMAT. PTV
in red and brain stem in cyan are made visible
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The EAR at the esophagus was one magnitude smaller
than at the thyroid. For the sake of simplicity we added
up both values. The corresponding boxplots are given in
Fig. 8. The risk has been reduced statistically significant
by the application of FFF mode. VMAT caused the low-
est dose and therefore the lowest risk of all techniques.
Plan verification
The previous results of the plan quality and the second-
ary malignancy risk demonstrated no benefit for the
non-coplanar techniques. Therefore, we verified the co-
planar plans only. All plans except of one IMRT plan
fulfilled the gamma value acceptance criteria. That
means that 95% of the pixels were within the tolerance
level mentioned in the material and methods section.
Discussion
Plan quality
No rescaling of the dose to the PTV has been performed
after the optimization as described in the section material
Fig. 4 HI (above) and CI (below) as boxplots for all plans: The boxes indicate the inner quartiles, the whiskers the outer quartiles. Outliers and
extreme values are indicated by circles and asterisks
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Fig. 5 Delivery time for the different plan groups from pressing the start button to the last beam off
Fig. 6 EAR for secondary brain cancer calculated by the mechanistic model, dependent on the different techniques. FFF (blue) is statistically
significant lower than FB (yellow)
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and methods. The failure of reaching the required dose
interval for the PTV of one plan could easily be corrected
in clinical routine by a rescaling of the MU. The
remaining treatment plan objectives would also have been
observed after rescaling, except of the chiasm. Choosing
other weights for the corresponding objectives of PTV
and chiasm might have avoided this little deviation but
would probably have impaired the values for HI and CI.
Goldsmith et al. [48] assume a tolerance dose of 54Gy for
radiation-induced optic neuropathy when applied in frac-
tions of 1.8 Gy. Therefore, our values were found
acceptable. An improved CI is an indicator of a conformal
high dose area and therefore of reduced risk for adverse
reactions in the organs at risk and unspecified tissue.
Consideration and observance of the dose volume ob-
jectives is a main criterion for the clinical acceptability
of a treatment plan. The dose limits were taken from
published recommendations and resulting risks for the
patient were regarded tolerable. No further ranking has
been derived from actually achieved mean dose values
below the limits. However, in individual cases, e.g. pre-
treated patients, further dose reduction in a selected
Fig. 7 a. EAR for secondary bone sarcoma dependent on the different techniques. b. EAR for secondary sarcoma of soft tissue dependent on the
different techniques
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organ at risk might be accomplished by another treat-
ment technique, setting, or mode.
The results regarding the plan quality cannot simply be
generalized to other equipment or tumors. Dobler et al.
found no difference in the application of IMRT or VMAT,
FB or FFF for patients with hypopharynx/larynx carcin-
oma [15]. Alvarez-Moret et al. stated in their study about
pediatric patients with ependymoma comparable HI and
CI for VMAT FB and FFF, but IMRT FFF superior to
IMRT FB [12]. Similarly were the results in an investiga-
tion about patients with localized prostate cancer [18].
The 2Fd and 3Fd plans were generated using a 5 mm
margin around the PTV. A larger margin probably
would improve the HI but also decrease the CI and in-
crease the volume of high dose to unspecified tissue and
organs at risk.
The reduction of delivery time in the application of
VMAT compared to IMRT was also found in the same
order for other entities [12, 18, 49], using the same
equipment. Most comparisons of FB and FFF in these
studies and also [29] found shorter or statistically not
significantly different DTs for FFF. Treutwein et al. [18]
discussed that additional MU are required to compen-
sate the profile fall off which also takes additional time.
And the potential higher dose rate cannot be exploited
between all control points, because the gantry speed and
also the speed of the collimating elements are limiting
factors [15]. In the present case these influences lead to
a slight increase in the DT which is of no clinical im-
portance. This result confirms that findings for other en-
tities cannot simply be transferred to all applications.
This has also been stated by Dobler et al. [15] who could
not confirm all advantages found for the re-irradiation
of spinal column metastasis [49] in their study about the
treatment of hypopharynx and larynx carcinoma with
the same equipment.
It might be surprising that VMAT can compete with
2Fd technique regarding the DT. However, there is one
switching off and on the beam less and there is no in-
active rotation time needed.
Secondary malignancy risk
Schneider et al. [40] presented plots of the EAR as a
function of the dose. The plot for the brain and central
nervous system shows all three models close together.
Although these plots end at a maximum dose of 40 Gy,
it seems natural that our results which are based on this
study, have also similar results for the three models.
Fractionation and recovery show only little influence in
the EAR. On the other hand there seems to be a de-
pendency on the irradiated volume. The risk increases
from 2Fd over 3Fd, IMRT9, up to the non-coplanar
VMAT2 technique.
Fig. 8 Summed EAR for secondary carcinoma at the peripheral organs thyroid and esophagus. FFF (blue) is statistically significant lower than
FB (yellow)
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The excess risk of sarcoma has been found one magni-
tude smaller than for carcinoma. This is in accordance
to the data of Preston et al. [41] of the A-bomb survi-
vors. Schneider et al. [40] concluded from data of radio-
therapy patients that the risk might be at comparable
magnitude for therapeutic doses. This has not been con-
firmed for our conditions.
It has been described in the background section that
other researchers found reduced PD when applying FFF
instead of FB which has been explicated by the missing
photon scatter from the flatness filter. Most of these works
confined to the documentation of the measured dose. In
the present work we calculated the resulting EAR. To our
knowledge, similar calculations have only been performed
by Murray et al. [17] for a small sample of three patients
with early prostate cancer and Alvarez-Moret et al. [12] in
a study of pediatric patients with ependymoma. Both con-
firmed a slightly lower EAR for FFF. The difference be-
tween FB and FFF in our study is statistically significant.
However, comparing the scales in Figs. 6 and 8 we find
the risk at the periphery some magnitude smaller than in
the treated region. The magnitude of this ratio is in ac-
cordance with the outcomes of Murray et al.
The calculated risks are based on mathematical
models and are not directly derived from clinical results.
Furthermore, they represent only a part of the risks to
which patients with pituitary adenomas are exposed in
radiotherapy. Therefore, our results can only support a
decision for a specific technique but other factors must
be considered.
Plan verification
The successful plan verifications show that there is no
technical problem in the application of FB and FFF,
IMRT and VMAT plans. This will probably also be true
for the non-coplanar techniques. A hybrid plan verifica-
tion with original couch angles would not have been
possible with our equipment: To avoid the irradiation of
the array electronics the patient table could not have
been turned to the original angle. As we could not dem-
onstrate any benefit for non-coplanar plans for our
standard setup we passed on their verification. However,
in individual cases, e.g. pretreated persons, their applica-
tion can be reasonable.
Conclusion
It has been shown that in the treatment of pituitary aden-
omas plans which use the FFF mode are of equal quality
as FB plans regarding the homogeneity, the conformity,
and the dose to the organs at risk. FFF plans are superior
in the respect of secondary malignancy induction. VMAT
is the fastest advanced technique, on the same level as op-
posing fields. Non-coplanar techniques showed no benefit
for the investigated parameters but need much more time
for couch rotation. Opposing fields cause the lowest sec-
ondary brain cancer risk but have the lowest conformity.
For most patients we regard VMAT the better choice
than IMRT due to slightly improved HI and CI and
clearly shortened treatment times. We regard the risk
for secondary malignancies as a minor effect which is of
the same magnitude for all techniques and modes. How-
ever, it can be used as a subordinated criterion with re-
duced risk using FFF. Taking all results into account
coplanar VMAT FFF seems the most preferable tech-
nique for the treatment of pituitary adenomas with the
given equipment.
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